AsclepiX Therapeutic
AsclepiX Therapeutics partners with Notal Vision on Home OCT remote monitoring in DME and AMD clinical trials
February 23, 2021 08:00 ET | Notal Vision
Manassas, VA, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Notal Vision, Inc. announced today that the company will provide AsclepiX Therapeutics with Home OCT monitoring services through its Notal Vision...
Notal Vision Launche
Notal Vision Launches First U.S. Home OCT Longitudinal Study with Patient Self-operated Device
January 12, 2021 08:00 ET | Notal Vision
Manassas, VA, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Notal Vision, Inc. announced today that the company initiated the first US-based study using its investigational home-based optical coherence...
AI-based OCT analysi
AI-based OCT analysis of AREDS2 10-Y follow-on study demonstrates superior performance over retina specialists
August 25, 2020 08:00 ET | Notal Vision
Manassas, VA, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Data analysis from Age-Related Eye Disease Study 2 10-year Follow-On Study (AREDS2-10Y) participants shows that the Notal Optical Coherence Tomography...
ForeseeHome AMD home monitoring real-world data analysis compares favorably to HOME study
July 28, 2020 08:00 ET | Notal Vision
Manassas, VA, July 28, 2020 (GLOBE NEWSWIRE) -- Real-world data on the performance of the ForeseeHome® AMD Monitoring Program, which helps detect the conversion from intermediate dry to wet...
Home OCT longitudinal home-based study with patient self-operated device has begun
June 17, 2020 07:30 ET | Notal Vision
Manassas, VA, June 17, 2020 (GLOBE NEWSWIRE) -- Notal Vision is proud to announce the enrollment of patients in the first longitudinal home-based study with its investigational home optical...
AI-based Notal OCT A
AI-based Notal OCT Analyzer successfully tracks exudative AMD disease activity across longitudinal data sets from home OCT and in-office OCT devices
February 25, 2020 06:00 ET | Notal Vision
Manassas, VA, Feb. 25, 2020 (GLOBE NEWSWIRE) -- The ability of the Notal OCT Analyzer (NOA™) to accurately track exudative age-related macular degeneration (AMD) disease activity across large...
AI-based retinal fluid analytics of serial Notal Vision home OCT images offers insights into retinal disease dynamics
February 11, 2020 08:00 ET | Notal Vision
Manassas, VA, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Longitudinal data on retinal imaging of age-related macular degeneration (AMD) patients using the final form factor of Notal Vision’s home OCT...
CPT codes for home O
CPT codes for home OCT established
January 08, 2020 08:00 ET | Notal Vision
Manassas, VA, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Notal Vision, Inc., a privately held ophthalmic diagnostic services company focused on advancing eye care with precision medicine by extending disease...
Notal Vision secures
Notal Vision secures $25 million in recent funding round for ForeseeHome® and pipeline technologies
December 11, 2019 08:00 ET | Notal Vision
Manassas, VA, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Notal Vision, Inc., a privately held ophthalmic diagnostic services company focused on advancing eye care with precision medicine by extending disease...
Notal Vision Announc
Notal Vision Announces Appointment of Dr. Kester Nahen as Chief Executive Officer
October 23, 2019 08:00 ET | Notal Vision
Tel Aviv, Israel, Oct. 23, 2019 (GLOBE NEWSWIRE) -- Notal Vision, Ltd., a privately held ophthalmic company focused on advancing eye care with precision medicine by extending disease management from...